International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Change From Baseline in Clinic Diastolic Blood Pressure (DBP) at Month 6

The change in clinic sitting DBP measured at Month 6 relative to baseline.

Time frame: Baseline and Month 6

Percentage of Participants With Response at Month 6

Response was defined as a decrease of SBP ≥20 mm Hg or a decrease of DBP ≥10 mm Hg.

Time frame: Month 6

Percentage of Participants Who Achieved Target Blood Pressure (BP) SBP<140 mm Hg and DBP<90 mm Hg

Time frame: Month 6

Change From Baseline in Clinic Systolic Blood Pressure (SBP) in Subgroups of Participants at Month 6

The change in clinic sitting SBP measured at Month 6 relative to baseline. Subgroups included overweight, obesity I (basic metabolic rate \[BMI\] 30-34.9), class II (BMI 35-39.9) and class III (BMI ≥ 40), impaired glucose tolerance, normal glucose metabolism, diabetes mellitus (Yes/No), metabolic syndrome, neither diabetes mellitus (DM) nor metabolic syndrome.

Time frame: Baseline and Month 6

Change From Baseline in Clinic Diastolic Blood Pressure (DBP) in Subgroups of Participants at Month 6

The change in clinic sitting DBP measured at Month 6 relative to baseline. Subgroups included overweight, obesity I (basic metabolic rate \[BMI\] 30-34.9), class II (BMI 35-39.9) and class III (BMI ≥ 40), impaired glucose tolerance, normal glucose metabolism, diabetes mellitus (Yes/No), metabolic syndrome, neither diabetes mellitus nor metabolic syndrome.